

In the Claims

Please amend the claims presented during the international phase as follows.

Applicant presents a full set of claims showing markups of the claims with insertions and deletions indicated by underlining and strikethrough text (or double bracketing), respectively.

1.-11. (Canceled)

12. (Original) A method for treating cancer, comprising
administering to a subject having a cancer characterized by reduced or absent LKB1 activity an effective amount of a compound that increases AMP-activated protein kinase (AMPK) activity in (cells of) the subject.

13.-16. (Canceled)

17. The method of claim 12, wherein the compound is metformin or an analog or derivative thereof that increases AMPK activity.

18.-20. (Canceled)

21. The method of claim 12, wherein the reduction of LKB1 activity is due to the mutation or deletion of the LKB1 gene.

22. The method of claim 12, further comprising subjecting the cancer (cells) of the subject to a cell death stimulus.

23.-30. (Canceled)

31. (Original) A method for promoting apoptosis of cells having reduced or absent LKB1 activity, comprising
contacting the cells with a compound that is an activator of AMP-activated protein kinase (AMPK).

32.-35. (Canceled)

36. The method of claim 31, wherein the compound is metformin or an analog or derivative thereof that increases AMPK activity.

37.-39. (Canceled)

40. (Original) The method of claim 31, wherein the reduction of LKB1 activity is due to the mutation or deletion of the LKB1 gene.

41.-70. (Canceled)

71. (New) The method of claim 17, wherein the analog of metformin is phenformin.

72. (New) The method of claim 36, wherein the analog of metformin is phenformin.